West Virginia hospital replacing computer system due to Petya cyberattack

The Petya cyberattack which has disrupted hospitals, radiology services and pharmaceutical companies is a forcing one West Virginia facility to scrap its entire computer network.

According to the Bluefield Daily Telegraph, Princeton Community Hospital is unable to access its electronic health records after the attack, though it said no patient information has been compromised. Services have been continuing, while non-emergency radiology requests have been delayed. To settle the computer issues, the hospital said it has begun replacing all the hard drives on all their devices.

“We are working to replace computer hard drives and to clean access to Meditech, our electronic medical record,” said Rose Morgan, RN, the hospital’s vice president of patient care services. “Several new computers were placed in strategic locations…to enable access to basic patient information from Meditech, such as the patient’s medical history, allergies, current medications, and other vital information to assist us in providing safe, quality patient care.”

Read the full article at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.